MedDataX Logo

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20161 in Healthy Volunteers

NCT ID: NCT02947139

Last Updated: 2017-02-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-29

Study Completion Date

2016-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, open label, crossover study to explore drug-drug interactions between DWC20155 / DWC20156 and DWC20161 in Healthy Volunteers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers

NCT02952755

Healthy
COMPLETED PHASE1

Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects

NCT02704559

Healthy
COMPLETED PHASE1

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20163 in Healthy Volunteers

NCT03005223

Healthy
UNKNOWN PHASE1

Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects

NCT06119958

Drug Drug Interaction
UNKNOWN PHASE1

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults

NCT07213310

Healthy
NOT_YET_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study effect of DWC20161 on DWC20155/DWC20156 PK

To study effect of DWC20161 on DWC20155/DWC20156 PK

Group Type EXPERIMENTAL

Co-administration of DWC20155/DWC20156

Intervention Type DRUG

DWC20161

Intervention Type DRUG

Study effect of DWC20155/DWC20156 on DWC20161 PK

To study effect of DWC20155/DWC20156 on DWC20161 PK

Group Type EXPERIMENTAL

Co-administration of DWC20155/DWC20156

Intervention Type DRUG

DWC20161

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Co-administration of DWC20155/DWC20156

Intervention Type DRUG

DWC20161

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Accepts healthy volunteers

Exclusion Criteria

* Who has allergy to investigational product
Minimum Eligible Age

19 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bundang CHA Medical Center

Gyunggi, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DW_DWJ1366003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects
NCT05699070 UNKNOWN PHASE1
The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults
NCT05321732 UNKNOWN PHASE1
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
NCT05574374 COMPLETED PHASE1
Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults
NCT04343547 UNKNOWN PHASE1
Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults
NCT06644404 NOT_YET_RECRUITING PHASE1
Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults
NCT05500898 UNKNOWN PHASE1
Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects
NCT02071381 COMPLETED PHASE1
Pharmacokinetics and Safety of DWJ1451 in Healthy Adults
NCT04819932 UNKNOWN PHASE1
Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects
NCT05106205 COMPLETED PHASE1
Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State
NCT05098275 COMPLETED PHASE1
Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition
NCT01606059 COMPLETED PHASE1
Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fasting State
NCT05108571 COMPLETED PHASE1
Drug-drug Interaction Study Between UIC201601 and UIC201602
NCT05190133 COMPLETED PHASE1
Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State
NCT05098262 COMPLETED PHASE1
Drug-drug Interaction Study Between UIC201603, and UIC201604
NCT06568133 COMPLETED PHASE1
Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930
NCT05207761 COMPLETED PHASE1
A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male Volunteers
NCT03005340 UNKNOWN PHASE1
Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904
NCT02243319 COMPLETED PHASE1
A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers
NCT05009368 COMPLETED PHASE1
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150
NCT04334213 COMPLETED PHASE1
Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501
NCT03089112 COMPLETED PHASE1
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
NCT05994807 COMPLETED PHASE1
Drug-Drug Interaction Between PK101-001 and PK101-002
NCT03553316 COMPLETED PHASE1
Drug-drug Interaction Study (CKD-501, Ketoconazole)
NCT01330563 COMPLETED PHASE1
Drug-Drug Interaction Study in Healthy Adult Volunteers
NCT02276001 COMPLETED PHASE1